Skip to main content

Health journal

Peptide Evidence, Safety and Regulation in Canada

Approved peptide medicines and online research chemicals are different categories. Evidence, product quality and the intended use all matter.

Dr. Colin MacLeod, ND
Dr. Colin MacLeod, ND
6 min read
On This Page

Peptides are promoted for recovery, weight loss, muscle gain and anti-aging, but the label covers very different products. Approved prescription medicines, investigational compounds, compounded preparations and online research chemicals differ in evidence, quality control and intended use.

Health Canada has warned against buying or injecting unauthorized peptide products sold online because they have not been assessed for safety, effectiveness or quality.1

What Are Peptides?

Peptides are short chains of amino acids. In the body, they often act as hormones, neurotransmitters, growth factors or signalling molecules. Their ability to interact with specific receptors can produce strong effects even at low doses.

Researchers can modify peptides to extend their half-life, improve selectivity or change how they are delivered.2 That biological activity also creates risk: dose, purity, route of administration and the person’s health all matter.

Approved Medicines and Other Products

Approved peptide medicines include insulin, GLP-1 receptor agonists, desmopressin and gonadotropin-releasing hormone analogues. Their uses range from diabetes care to specific endocrine, bleeding and reproductive conditions. Tesamorelin is approved in some jurisdictions for HIV-associated lipodystrophy.

These medicines undergo regulatory review, with defined manufacturing standards, dosing, storage, contraindications and adverse-effect information. They are not risk-free, but their benefits and risks are evaluated for specific uses.

Other categories need to be considered separately:

  • Investigational peptides are being studied in clinical trials. Evidence depends on the molecule, intended use and stage of research.
  • Compounded preparations are patient-specific products, distinct from federally authorized manufactured medicines.
  • Online research chemicals, including BPC-157, TB-500 and CJC-1295, raise questions about evidence, purity, sterility and dosing.
  • Cosmetic peptides and oral collagen products have different uses and routes of administration. Evidence for one product does not establish a claim for another.

Canadian Regulation

In April 2026, Health Canada issued a public advisory warning people not to buy or use unauthorized injectable peptide medicines sold online. The advisory listed examples of seized products, including BPC-157, CJC-1295, DSIP, epitalon, GHK-Cu, HCG, ipamorelin, KPV, melanotan I and II, MOTS-c, NAD+, SS-31, TB-500 and retatrutide.1

Health Canada stated that peptides are generally regulated as prescription medicines in Canada, and that authorized medicines for sale in Canada have an eight-digit Drug Identification Number (DIN). Products labelled “For Research Use Only” are not made legal for human use by that label. Health Canada’s concern is not only whether the peptide itself might work; it is also whether the product has been assessed for safety, efficacy and quality.

Health Canada has also addressed GLP-1 compounding specifically. In a June 2025 position document, the regulator noted the rise of unauthorized and counterfeit semaglutide products and stated that sterile compounding is a high-risk activity that should generally be reserved for exceptional circumstances, such as a patient-specific need that cannot be met by an approved drug or a true shortage. Health Canada also expressed concern about compounded GLP-1 products mixed with other active ingredients without scientific justification.3 In April 2026, Health Canada authorized a generic semaglutide injection, which is a useful reminder that an approved synthetic peptide medicine is very different from an unauthorized compounded or online product.4 A peptide being “available” online does not mean it is authorized, legal for sale, sterile, accurately dosed or appropriate for human use.

What the Evidence Shows

Performance and recovery peptides: BPC-157 and TB-500 are commonly discussed for tendon, ligament, gut and injury healing. BPC-157 has a large amount of animal and laboratory research, but there is a major gap between animal data and reliable human clinical evidence. As of this writing, there is no robust body of published, large, randomized human trials showing that BPC-157 safely and effectively treats common sports injuries in people. That gap should matter when claims are presented as established fact.

Growth hormone secretagogues: CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin and related compounds are promoted for body composition, recovery, sleep and anti-aging. Their mechanisms are plausible because they can influence growth hormone and insulin-like growth factor-1 signalling. But changing this axis can also create side effects, including fluid retention, changes in glucose regulation, carpal tunnel-like symptoms, headaches and theoretical concerns in people with cancer risk or proliferative disease. Long-term safety for broad wellness use is not well established.

Melanotan products: Melanotan II is promoted for tanning and libido. It has been associated with nausea, flushing, changes in moles, priapism and case reports of more serious events, including renal infarction.5 It is a good example of how a product marketed as cosmetic or lifestyle-oriented can still have systemic medicine effects.

Product Quality and Injection Risks

Many peptide products are injected subcutaneously. Injection changes the risk profile. A contaminated oral supplement is concerning; a contaminated injectable is more concerning because it bypasses several normal barriers. Sterility, endotoxin control, particulate contamination, solvent residues, accurate concentration and cold-chain storage all matter.

Health Canada specifically warned that unauthorized peptide products may contain too much, too little or none of the active ingredient. They also may contain unlisted or dangerous ingredients, such as solvents, heavy metals, glass, plastic, fibers, bacteria, fungi or endotoxins. They also may be poorly labelled, improperly manufactured or improperly stored.1

This is one of the central problems with the research chemical market. A certificate of analysis posted by a vendor is not the same thing as independent pharmaceutical quality assurance. It may not apply to the actual vial received. It may not include sterility or endotoxin testing. It may not detect all impurities. It may also be fabricated or selectively presented. For an injectable medicine, quality control is not a minor detail.

Reading Claims Critically

A plausible mechanism or promising animal study is a starting point for research, not proof of a benefit in people. Dose, metabolism, disease models and outcomes may not translate. Peptide development is expensive, and evidence can lag behind demand; early promise may also fail to translate into benefit or reveal safety problems.

Marketing often gives a complex molecule a simple story: a “healing peptide,” “growth hormone optimization stack” or “mitochondrial peptide.” Personal experience can suggest questions worth studying, but anecdotes are affected by placebo effects, natural recovery, concurrent treatments, training and diet changes, selective reporting and financial incentives.

“Natural” does not establish safety. Many marketed peptides are synthetic analogues or modified compounds, and comparisons with steroids overlook different risks involving growth hormone, glucose metabolism, pigmentation, immune signalling or fertility hormones. Long-term uncertainty still matters.

Sport and Anti-Doping

Peptides are prominent in bodybuilding because many are marketed for muscle gain, fat loss, recovery, appetite control or injury repair. Competitive athletes have another issue: anti-doping rules.

The World Anti-Doping Agency’s 2026 Prohibited List includes multiple peptide-related categories. Growth hormone, growth hormone fragments, growth-hormone-releasing hormone analogues such as CJC-1295 and sermorelin, growth hormone secretagogues such as ipamorelin and ibutamoren, and GH-releasing peptides such as GHRP-2 and GHRP-6 are prohibited at all times.6 The list also includes other growth factors and hormone-modulating substances. Athletes subject to anti-doping rules should not assume that a clinic, supplement store, online vendor or influencer has checked the current prohibited list.

For recreational bodybuilders, the issue is less about sanctions and more about risk normalization. Communities that are comfortable with anabolic steroids, growth hormone, insulin or research chemicals may understate the medical uncertainty of peptides. The fact that a compound is commonly used in a community does not establish safety.

Questions That Matter

A useful assessment asks whether a specific peptide, from a specific source, for a specific person and purpose, has enough evidence and quality control to justify its risks. Availability online, a research-use label or an influencer’s experience cannot answer those questions.

References

  1. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you. Public advisory. April 9, 2026.
  2. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nature Reviews Drug Discovery. 2021;20:309-325.
  3. Health Canada. Health Canada’s position on the unauthorized manufacturing of products sold as compounded glucagon like peptide 1 (GLP-1) receptor agonists. June 2, 2025.
  4. Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. News release. April 28, 2026.
  5. Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Reports. 2020;9(2):159-161.
  6. World Anti-Doping Agency. The 2026 Prohibited List: International Standard. In force January 1, 2026.
  7. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorganic & Medicinal Chemistry. 2018;26(10):2700-2707.
  8. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018;27(4):740-756.
  9. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002.
  10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216.
  11. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
  12. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Updated 2026.